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Abstract:  Marine-derived fungi provide plenty of structurally unique and biologically 
active secondary metabolites. We screened 87 marine products from mangrove fungi in the 
South China Sea for anticancer activity by MTT assay. 14% of the compounds (11/86) 
exhibited a potent activity against cancer in vitro. Importantly, some compounds such as 
compounds 78 and 81 appeared to be promising for treating cancer patients with multidrug 
resistance, which should encourage more efforts to isolate promising candidates for further 
development as clinically useful chemotherapeutic drugs. Furthermore, DNA intercalation 
was not involved in their anticancer activities, as determined by DNA binding assay. On 
the other hand, the structure-activity analysis indicated that the hydroxyl group was 
important for their cytotoxic activity and that bulky functional groups such as phenyl rings 
could result in a loss of biological activity, which will direct the further development of 
marine product-based derivatives.   
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1. Introduction 
The majority of species are found in the oceans, which constitute 70% of the world’s surface. 
Marine organisms are a rich source of chemical products [1,2]. In recent years, a renaissance has 
occurred in marine pharmacology. Complex and highly chiral structures have been optimized by high 
salt concentrations and high pressure environments over millions of years, which confers marine 
organisms the potential to produce valuable therapeutic entities [3,4]. Emerging evidence suggests that 
marine natural products, especially the secondary metabolites from marine organisms, are far more 
likely to yield anticancer drugs than terrestrial sources [1,5]. For example, Arc-C (cytarabine, an 
antileukemic drug) and trabectedin (Yondelis, ET-743, an agent for treating soft tissue sarcoma) were 
developed from marine sources [3,6]. Mangroves, a kind of special host plants, are a resource of 
abundant endophytic fungi. Marine-derived fungi have proven to be a rich source of structurally 
unique and biologically active secondary metabolites [7]. In the last decade, there has been a dramatic 
increase in the number of preclinical anticancer lead compounds extracted from metabolites of 
marine-derived fungi [8–10].   
Chemotherapy is currently the primary treatment modality in many tumors. However, the 
development of multidrug resistance (MDR) to chemotherapeutic drugs is a main obstacle for the 
successful treatment of malignant tumors. One of the best known mechanisms of MDR is the 
overexpression of ATP-binding cassette (ABC) transporters that actively pump drugs out of tumor 
cells [11,12]. Therefore, the development of novel chemotherapeutic agents would play a key role in 
the treatment of refractory or relapsing cancer patients. Nowadays, the chemical, biological and 
ecological diversity of the marine ecosystem has contributed immensely potent antitumor compounds 
[13]. It is believed that a rich source of anticancer drug candidates could be obtained from marine 
organisms or their metabolites. In this paper, we describe qualitative structure-activity relations for a 
number of mangrove-derived secondary metabolites. Some further compounds have not been obtained 
from nature and will be described in detail later elsewhere. 
2. Results and Discussion 
Eighty-six compounds isolated and identified from metabolites of mangrove fungi in the South 
China Sea were screened for activity inhibiting cancer cell growth by MTT assay. Eleven of them 
showed potent cytotoxic activity in KB, KBv200, MCF-7, MCF-7/adr, and A549 cells, with IC50 
values less than 50 μmol/L. These are the compounds 1, 4, 7, 8, 9, 11, 13, 14, 18, 78 and 81. 
Importantly, compounds 78 and 81 exhibited similar IC50 values in both ABCB1/P-glycoprotein (P-gp) 
overexpressing MDR cells such as KBv200, MCF-7/adr and their parental sensitive cells such as KB, 
MCF-7 (Table 1). These results suggest that we found some lead compounds from marine production 
and some are promising to treat MDR cancer patients.   Mar. Drugs 2010, 8  
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Table 1. Cytotoxic effect of marine products in human cancer cells and a normal liver LO2 cells. 
Compound 
IC50 value (μmol/L) 
KB KBv200  MCF-7  MCF-7/adr  A549  LO2 
Doxorubicin  0.05 ± 0.003  3.21 ± 0.12  0.39 ± 0.02  22.33 ± 1.56  1.67 ± 0.09  0.11 ± 0.01 
Multi-substituent phenyl derivatives 
1  1.57 ± 0.08  2.67 ± 0.17  1.38 ± 0.07  2.34 ± 0.11  2.71 ± 0.15  6.59 ± 0.44 
2  >50 >50 >50 >50 >50 >50 
3  >50 >50 >50 >50 >50 >50 
4  1.15 ± 0.06  6.74 ± 0.38  11.74 ± 0.86  35.67 ± 2.08  17.10 ± 1.03  16.48 ± 1.22 
5  >50 >50 >50 >50 >50 >50 
6  >50 >50 >50 >50 >50 >50 
Mangrove-derived quinones   
7  0.03 ± 0.001  9.08 ± 0.65  0.17 ± 0.01  31.56 ± 1.83  16.51 ± 0.88  47.35 ± 2.04 
8  0.71 ± 0.03  17.20 ± 0.96  2.53 ± 0.14  9.37 ± 0.42  >50  >50 
9  0.94 ± 0.01  47.98 ± 3.41  1.43 ± 0.09  31.60 ± 1.36  >50  >50 
10  >50 >50 >50 >50 >50 >50 
11  5.89 ± 0.37  18.94 ± 1.20  13.23 ± 0.84  35.34 ± 2.77  21.34 ± 1.60  28.88 ± 1.46 
12  >50 >50 >50 >50 >50 >50 
13  21.00 ± 1.35  >50  16.32 ± 0.71  >50  31.23 ± 2.02  >50 
14  11.86 ± 0.69  >50  35.23 ± 1.87  >50  23.53 ± 1.32  37.51 ± 1.64 
15  >50 >50 >50 >50 >50 >50 
16  >50 >50 >50 >50 >50 >50 
17  >50 >50 >50 >50 >50 >50 
18  28.19 ± 1.66  44.63 ± 2.57  17.22 ± 0.95  24.96 ± 1.06  33.89 ± 2.31  >50 
19  >50 >50 >50 >50 >50 >50 
20  >50 >50 >50 >50 >50 >50 
21  >50 >50 >50 >50 >50 >50 
22  >50 >50 >50 >50 >50 >50 
23  >50 >50 >50 >50 >50 >50 
24  >50 >50 >50 >50 >50 >50 
25  >50 >50 >50 >50 >50 >50 
Isoflavone analogs 
78  8.63 ± 0.57  9.37 ± 0.61  19.77 ± 0.89  24.95 ± 1.15  14.88 ± 0.64  33.62 ± 2.06 
79  >50 >50 >50 >50 >50 >50 
80  >50 >50 >50 >50 >50 >50 
Fatty acid derivatives 
81  0.37 ± 0.01  0.39 ± 0.02  0.41 ± 0.02  0.49 ± 0.02  0.34 ± 0.01  0.72 ± 0.03 
82  >50 >50 >50 >50 >50 >50 
83  >50 >50 >50 >50 >50 >50 
84  >50 >50 >50 >50 >50 >50 
85  >50 >50 >50 >50 >50 >50 
86  >50 >50 >50 >50 >50 >50 
 
To understand whether the compounds are specially targeting the cancer cells rather than normal 
cells, we compared the effect of the compounds on inhibiting cell growth in cancer cells and normal 
cells. The results showed cancer cells were more sensitive to compounds 1, 18, 78 and 81 than the Mar. Drugs 2010, 8  
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normal liver LO2 cells. However, compound 4 and 11 also exhibited growth inhibitory activity in LO2 
cells. Of course, the toxicity of the compounds needs further study.   
The core structure of compounds 7–10 is a xanthone, which is a main constituent in the mangosteen 
fruit and was firstly isolated from marine products. Xanthone has potent antioxidant and anticancer 
activities and regulates the function of immunity [14]. Compounds 11–19 are anthraquinones, which 
have been demonstrated to exert various physiological activities such as antibiotic and anticancer 
properties [10,15,16]. Similar to doxorubicin, compound 7, 9, 13, 14, exhibited much higher IC50 
values in MDR cells such as KBv200 cells and MCF-7/adr cells than in parental sensitive cells such as 
KB cells and MCF-7 cells (Table 1). This suggests that MDR cells are extremely resistant to 
compound 7, 9, 13, 14, which may be substrates of the multidrug resistant transporter 
ABCB1/P-glycoprotein.  
The analysis of structure-activity is important to direct further synthesis. Compared with compound 
1, compounds 2, 3 and 5 lack one or two hydroxyl groups, whereas compound 6 has an altered position 
of the hydroxyl group, which apparently is responsible for loss of cytotoxic activity among six 
multi-substituent phenyl derivatives (Figure 1). However, the cytotoxic effect was maintained in 
compound 4 in which the nitro-substituent was absent. This suggests that the para-positioned hydroxyl 
group is necessary in these compounds to inhibit cancer cells growth. 
Figure 1. The chemical structures of six multi-substituent phenyl derivatives. 
 
The 5-hydroxyl group was critical to the antitumor activity in quinone derivatives, whereas a phenyl 
ring was found to result in a loss of activity (Figure 2, Table 1) among compound 7–25. On the other 
hand, the tetracycline analogs, compounds 20–25, were found to be devoid of any cytotoxic activity. Mar. Drugs 2010, 8  
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Figure 2. Chemical structures of 19 quinone analogs. 
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The coumarin was the precursor for several anticoagulants [17]. The coumarin derivatives 
(compound 26–69) did not demonstrate significant cytotoxic activity (IC50 > 50 µmol/L). Their 
chemical structures are shown in Figure 3.   
Figure 3. Chemical structures of 44 coumarin analogs. 
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The compounds 70–74 belong to xyloketal analogs, condensed ring compounds [18,19]. No 
appreciable antitumor activity was found for these eight compounds (IC50 > 50 µmol/L). Their 
chemical structures are exhibited in Figure 4. 
Figure 4. The chemical structures of eight condensed ring compounds. 
 
The compound 78 is an isoflavone analog, which was reported to have a preventive effect against 
various cancers [20,21]. It exhibited a cytotoxicity targeted to cancer cells. However, its analogs, the 
compounds 79 and 80, were not found to inhibit cell growth in cancer cells (IC50 > 50 µmol/L). The 
compound 81, a prostaglandin analog and fatty acid derivative, showed potent anticancer activity in 
vitro by MTT assay. However, compounds 82–86, fatty acid derivatives with similar structure to 
compound 81, did not show anticancer activity (Table 1). The structures of the compounds 78–86 are 
shown in Figure 5. 
As we know, the intercalation of DNA is an important mechanism for several chemotherapeutical 
drugs such as doxorubicin and cisplatin, and many others [10]. Therefore, we examined the ability of 
the compounds whose IC50 value was less than 50 μmol/L to intercalate into DNA. Compounds 1, 4, 
7–9, 11, 13, 14, 18, 78 and 81 were included. The results show that doxorubicin as a standard 
effectively intercalated into DNA in a concentration-dependent manner. However, none of the 
compounds investigated here showed binding to DNA even at a very high concentration (Figure 6). 
These results indicated that DNA intercalation is not involved in the cytotoxic effect induced by these 
compounds. Mar. Drugs 2010, 8  
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Figure 5. Chemical structures of three isoflavonoid analogs and six fatty acid derivatives. 
 
Figure 6. The ability of 11 compounds with IC50 value less 50μmol/L to intercalate into 
DNA. A representative gel image after electrophoresis of the treated DNA vector on 1% 
agarose for 40 min. The results show that doxorubicin (Dox), a positive control, effectively 
intercalated to DNA in concentration-dependent manner. However, no compound showed 
DNA binding in the concentrations of 10 (L), 100 (M) or 200 (H) µmol/L. 
 
In conclusion, we screened 86 marine products for anticancer activity by MTT assay. There were 
14% (11/86) compounds that exhibited a potent activity against cancer in vitro. The analysis of 
structure-activity will direct the further development of marine product-based derivatives. Importantly, 
some compounds, such as compound 78 and 81, appeared to be promising in treating MDR  
cancer patients.   Mar. Drugs 2010, 8  
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3. Experimental Section   
3.1. Chemicals and reagents 
Doxorubicin (DOX), 3-(4,5-dimethylthiazol-yl)-2,5-diphenyltetrazolium bromide (MTT) and other 
chemicals were obtained from Sigma Chemical Co. (San Diego, CA, USA). Dulbecco’s modified 
Eagle’s medium (DMEM) and RPMI 1640 were products of Gibco BRL. 
3.2. Isolation of compounds from metabolites of marine-derived fungi 
Marine-derived fungi were isolated from the mangroves of the South China Sea. The fungi numbers 
were Phomopsis sp. ZSU-H76  [22], Phomopsis sp. ZZF08  [23], Paecilomyces sp. (tree 1–7)  [24], 
Sargassum sp. ZZF36  [25], Halorosellinia sp. No. 1403  [26], SBE-14  [27] and B60  [28]. All 
compounds were isolated by She Zhigang, a professor at Sun Yat-Sen University. The structures were 
elucidated by comprehensive spectral analysis, including 2D NMR spectroscopy.   
3.3. Tumor cell culture 
The cell lines were cultured in DMEM or RPMI 1640 containing 10% fetal bovine serum at 37 °C 
in the presence of 5% CO2. The cell lines were the oral epidermoid carcinoma cell lines KB and its 
vincristine-selected ABCB1-overexpressing KBv200 [10]; the breast carcinoma
 cell lines MCF-7 and 
its doxorubicin-selected ABCB1-overexpressing MCF-7/adr [29]; the lung carcinoma
 cell line A549 
and normal liver cell line LO2. 
3.4. Anticancer activity assays 
The MTT assay was used to evaluate the cytotoxicity of a number of compounds previously 
isolated from mangrove-derived fungi as described [30,31]. Briefly, 3–4 × 10
3 cells were incubated in 
96-well plates and allowed to attach overnight before compounds at full range concentrations were 
added. The concentrations were chosen so that the highest concentration killed most of the cells and 
the lowest killed none of the cells. After 72 h treatment, 0.5 mg/ml MTT was added to each well for an 
additional 4 h. Subsequently, the supernatant was removed, and the purple MTT-formazan crystals 
were dissolved by DMSO. Finally, absorbance was recorded at 540 nm with 655 nm as a reference 
filter using a Model 550 Microplate Reader (Bio-Rad, USA). Experiments were performed at least 
three times. The standard chemotherapeutic agent doxorubicin was used as a positive control in MTT 
assay and normal liver cell line LO2 was used to show whether cytotoxic activity was tumor-specific. 
The concentrations required to inhibit growth by 50% (IC50) were calculated from survival curves 
using the Bliss method. 
3.5. DNA binding assay 
10, 100 or 200 µmol/L compounds were incubated with 1 µg pcDNA3.1(+) at 37 °C for 3 h. The 
mixtures were then subjected to electrophoresis on a 1% agarose gel, pre-stained with 0.5 µg/ml 
ethidium bromide, at 60 V for 40 min. Doxorubicin (DOX) was used as a positive control. Mar. Drugs 2010, 8  
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